Efficacy of sutureless and glue-free conjunctival autograft compared with sutured conjunctival autograft in pterygium surgery: a meta-analysis Authors: Chengxiao Zhang, Zeying Chen, Jiaxuan Jiang, Junwen Ouyang, Kai Hu Published: 2026 ABSTRACT AbstractThis study compared sutureless and glue-free conjunctival autograft (SGC) with sutured conjunctival autograft (control) in pterygium surgery in terms of key outcome measures, including recurrence rate, complication rate, and surgical duration, to evaluate the efficacy and safety of SGC. A comprehensive search of five databases (PubMed, Web of Science, China National Knowledge Infrastructure, Wanfang Data, and China Science and Technology Journal Database) was conducted to identify relevant studies. Dichotomous outcomes were analyzed using relative risk (RR), and continuous outcomes were analyzed using mean difference (MD). The 95% confidence intervals (CIs) provided a measure of the precision of the estimates. The study included a total of 1,233 eyes from 11 studies. The pooled estimates for recurrence rate (RR = 0.65; 95% CI, 0.42–1.01) and overall complication rate (RR = 1.24; 95% CI, 0.68–2.25) revealed no statistically significant differences between SGC and control groups. However, the pooled estimates for graft dehiscence (RR = 4.73; 95% CI, 1.29–17.28) and graft retraction (RR = 3.09; 95% CI, 1.56–6.15) indicated higher incidences of these complications in the SGC group. Furthermore, the analysis of surgical duration revealed a statistically significant reduction in surgical duration in the SGC group (MD= – 12.79; 95% CI, – 18.04 to – 7.53). This meta-analysis demonstrates that, compared with the control group, SGC can significantly shorten surgical duration without increasing the recurrence rate in the treatment of pterygium, although it is associated with higher rates of graft dehiscence and graft retraction. Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-54305-6.Keywords: Meta-analysis, Ophthalmic surgery, Pterygium, Conjunctival autograftSubject terms: Diseases, Medical research Introduction Pterygium is a fibrovascular proliferation originating from the bulbar conjunctiva and extending onto the corneal surface1,2. It may cause ocular irritation and cosmetic concerns, induce corneal astigmatism, and lead to visual impairment when it encroaches on the visual axis3. The prevalence of pterygium increases with advancing age4,5 and ranges from 2.8% to 53% in different populations and geographic regions6–9. Surgical intervention is the primary approach for managing pterygium. Initially, the classic bare sclera technique, introduced by D’Ombrain in 194810, was employed. However, due to its high recurrence rate, this method is no longer recommended. Conjunctival autograft, proposed by Kenyon et al. in 198511, has since become the standard treatment for pterygium. It is associated with a significantly lower recurrence rate, ranging from 2% to 39%, compared with the recurrence rate of 30% to 88.9%12 reported for the bare sclera technique13. Despite its efficacy, suturing during surgery is a meticulous and time-consuming task14, which can result in complications such as pain, irritation, redness, and foreign body sensation15. In 2004, Koranyi et al.16 introduced fibrin glue (FG) as an alternative to sutures in pterygium surgery. FG offers advantages such as a shorter surgical duration, improved patient comfort, and a lower recurrence rate17. However, it also has certain limitations, including cost considerations and the potential for complications such as graft dehiscence, graft retraction, and suppurative granuloma formation18. Additionally, plasma-derived FG may carry the risk of prion disease transmission and allergic reactions in susceptible individuals19. Sutureless and glue-free conjunctival autograft (SGC) is a technique in which the conjunctival autograft is placed over the bare scleral defect after pterygium excision without sutures or fibrin glue. The graft is stabilized mainly by autologous blood coagulation and tissue adhesion20. In 2013, Xu et al.21 incorporated the electrocautery pen (ECP) into SGC procedures for pterygium, while Yan et al.22 developed a modified SGC fixation method. In procedures involving ECP, the device was employed to bond one corner of the graft to the corresponding conjunctiva. Regarding the modified SGC fixation method, the conjunctival autograft was flattened and secured by a strabismus hook, with gentle pressure applied to eliminate blood or exudate beneath it. These modifications aimed to enhance the efficacy of SGC while reducing the risk of recurrence and postoperative discomfort. This meta-analysis aimed to comprehensively assess the efficacy and safety of SGC as a treatment option for pterygium by comparing it with sutured conjunctival autograft in terms of key outcome measures, including recurrence rate, complication rate, and surgical duration. Methods The present meta-analysis adhered to the guidelines outlined in the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement23. S Tables 1 and 2 contain the PRISMA checklists for reference. Search strategy Electronic databases, including PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), Wanfang Data, and China Science and Technology Journal Database (VIP), were systematically searched to identify relevant published articles. The complete search strategy can be found in S Fig. 1. This search was conducted without imposing any restrictions based on language, methodological filters, or year of publication. The final search was performed on February 19, 2026. Flowchart of the literature search and selection progress in this meta-analysis. Inclusion and exclusion criteria The inclusion criteria for this meta-analysis were as follows: (1) studies including patients with a preoperative diagnosis of primary pterygium and clear surgical indications; (2) randomized controlled trials (RCTs) directly comparing SGC with sutured conjunctival autograft; and (3) studies reporting recurrence rate and at least one secondary outcome (complication rate or surgical duration). The exclusion criteria were as follows: (1) studies for which the full text was unavailable; (2) meta-analyses, abstracts, summaries, or non-clinical studies; (3) studies in which the sample size in either group was less than 10; and (4) studies with a follow-up time of less than six months. Data extraction and quality assessment Two independent reviewers performed the initial screening of articles based on the predefined inclusion criteria. Any disagreements or discrepancies arising during the screening process were resolved through discussion and consensus. Relevant information and data were extracted from the selected articles, including the first author, year of publication, country, study type, sample size, mean age of participants, number of recurrences, number of adverse events, surgical technique, surgical duration, and follow-up time. RCTs were evaluated using the Cochrane risk of bias assessment tool in Review Manager 5.4 (RevMan 5.4; The Cochrane Collaboration, Copenhagen, Denmark). Outcome measures and relevant definitions This meta-analysis focused on three primary outcome measures to assess the effectiveness and safety of the interventions under investigation. (1) Recurrence rate: The recurrence rate served as a key endpoint in this analysis. It was calculated based on data collected from each study at the end of follow-up. (2) Complication rate: The overall complication rate included graft dehiscence, graft retraction, graft hemorrhage, granulomas, conjunctival edema, and cyst formation. In addition to the overall complication rate, separate meta-analyses were performed for three major complications with sufficient available data: graft dehiscence, graft retraction, and granulomas. (3) Surgical duration: Surgical duration served as an important factor in assessing the practicality and efficiency of the different surgical techniques being studied. Statistical analysis The statistical analysis for this meta-analysis was conducted using two software packages: RevMan 5.4 and StataMP 17 (StataCorp LLC, TX, USA). Relative risk (RR) was used as the effect measure for dichotomous outcomes24, whereas mean difference (MD) was used for continuous outcomes. The pooled estimates for all outcome measures were calculated using random-effects models and were accompanied by 95% confidence intervals (CIs) to provide a measure of the precision of the estimates. Statistical heterogeneity was assessed using the I2 and H2 values, and potential sources were explored by meta-regression. Subgroup analyses were conducted based on the surgical technique used in the SGC group. Sensitivity analyses were performed using the leave-one-out method. Additionally, funnel plots were generated and Harbord tests were performed to assess the possibility of publication bias in the main outcomes. When publication bias was detected, its potential impact was further evaluated using the trim-and-fill method. Results Literature search A total of 488 records were retrieved from the five selected databases. After initial screening, 423 records were excluded because they were unavailable as full-text articles or were duplicates across databases (n = 201), were not randomized controlled trials (n = 4), did not compare SGC with sutured conjunctival autograft (n = 214), or did not report recurrence rate or any secondary outcome (n = 4). The remaining 65 full-text articles were assessed for eligibility. Of these, 52 articles were excluded because they were meta-analyses, abstracts, summaries, or non-clinical studies, and two articles were excluded because the follow-up duration was less than six months. Ultimately, 11 studies met the eligibility criteria and were included in this meta-analysis. The entire literature selection process is visually represented in Fig. 1, providing an overview of the steps taken to identify and include the relevant studies in the meta-analysis. Characteristics and quality of included studies Of the 11 included RCTs in Table 1, five were conducted in China21,22,25–27, four in India28–31, and the remaining two in Egypt19 and Nepal32, respectively. In total, the analysis encompassed 1,233 eyes, with 595 eyes in the SGC group and 638 eyes in the sutured conjunctival autograft (control) group. In the SGC group, nine studies utilized auto-coagulation in situ as part of the surgical procedure, while two studies used ECP. Among the 11 included studies, eight had a follow-up time of up to 12 months, while the remaining three provided sufficient explanations for shorter follow-up time. Table 1Characteristics of Included Studies.The First AuthorYearCountrySample Size, eyeAge, yearSurgical TechniqueFollow-up Time, monthSGCControlSGCControlFan Xu2013China404057.153.6ECP12Shaaban A.M. Elwan2014Egypt501004949Auto-coagulation24Somnath Choudhury2014India16164545Auto-coagulation12Alok Sati2014India303040.6340.9Auto-coagulation12Ashok Sharma2015India252542.6543.77Auto-coagulation6Tanie Natung2017India151544.7744.77Auto-coagulation6Bin Yan2019China39346062Auto-coagulation12Dikshya Bista2021Nepal505046.7647.24Auto-coagulation12Jidong Zuo2022China21721556.6356.97Auto-coagulation6Tao Li2023China838355.1152.01ECP12Guanghui Cai2023China303066.2566.08Auto-coagulation12 Characteristics of Included Studies. Figures 2 and 3 showed that the quality of these 11 RCTs was relatively high. However, some risk of bias domains remained unclear due to insufficient information reported in certain included studies. Risk of bias graph: review authors’ judgment of each item at risk of bias was expressed as a percentage across all included studies. Risk of bias summary: review authors’ judgment of each item at risk of bias for each included study. Outcome measures Recurrence rate The recurrence rate is a critical outcome measure for evaluating the effectiveness of pterygium treatment, defined as the proportion of eyes with recurrence at the end of follow-up in each group. As shown in Table 2, the reported recurrence rate ranged from 0% to 26.7% in the SGC group and from 2.9% to 33.3% in the control group. Table 2Outcome Measures of Included Studies.The First AuthorSurgical TechniqueRecurrence RateOverall Complication RateSurgical Duration(-x±s, min)SGCControlSGCControlSGCControlShaaban A.M. ElwanAuto-coagulation6.00%(3/50)8.00%(8/100)48.00%(24/50)27.00%(27/100)24 ± 5.6428.64 ± 6.45Somnath Choudhury6.30%(1/16)6.30%(1/16)12.50%(2/16)6.30%(1/16)15 ± 267 ± 2Alok Sati3.30%(1/30)10.00%(3/30)20.00%(6/30)0.00%(0/30)16.97 ± 1.3527.63 ± 1.63Ashok Sharma0.00%(0/25)4.00%(1/25)8.00%(2/25)16%(4/25)23.2 ± 1.5537.76 ± 1.89Tanie Natung26.70%(4/15)33.30%(5/15)4.00%(6/15)0.00%(0/15)Not MentionedNot MentionedBin Yan0.00%(0/39)2.90%(1/34)15.40%(6/39)0.00%(0/34)11.19 ± 1.324.3 ± 6.1Dikshya Bista8.00%(4/50)14.00%(7/50)28.00%(14/50)10.00%(5/50)20.18 ± 2.0822.14 ± 1.79Jidong Zuo3.70%(8/217)3.30%(7/215)7.80%(17/217)11.60%(25/215)21.15 ± 1.8930.47 ± 1.09Guanghui Cai3.30%(1/30)20.00%(6/30)6.70%(2/30)26.70%(8/30)28.92 ± 2.3736.59 ± 1.41Fan XuECP5.00%(2/40)7.50%(3/40)5.00%(2/40)5.00%(2/40)20.4 ± 2.127.1 ± 1.7Tao Li4.80%(4/83)9.60%(8/83)9.60%(8/83)18.10%(15/83)26.38 ± 2.5033.75 ± 1.46 Outcome Measures of Included Studies. 6.00% (3/50) 8.00% (8/100) 48.00% (24/50) 27.00% (27/100) 6.30% (1/16) 6.30% (1/16) 12.50% (2/16) 6.30% (1/16) 3.30% (1/30) 10.00% (3/30) 20.00% (6/30) 0.00% (0/30) 0.00% (0/25) 4.00% (1/25) 8.00% (2/25) 16% (4/25) 26.70% (4/15) 33.30% (5/15) 4.00% (6/15) 0.00% (0/15) 0.00% (0/39) 2.90% (1/34) 15.40% (6/39) 0.00% (0/34) 8.00% (4/50) 14.00% (7/50) 28.00% (14/50) 10.00% (5/50) 3.70% (8/217) 3.30% (7/215) 7.80% (17/217) 11.60% (25/215) 3.30% (1/30) 20.00% (6/30) 6.70% (2/30) 26.70% (8/30) 5.00% (2/40) 7.50% (3/40) 5.00% (2/40) 5.00% (2/40) 4.80% (4/83) 9.60% (8/83) 9.60% (8/83) 18.10% (15/83) The results shown in Fig. 4 revealed no statistically significant difference in recurrence rate between the SGC and control groups (RR = 0.65; 95% CI, 0.42–1.01). Subgroup analyses also indicated that there was no statistically significant difference for either the auto-coagulation in situ subgroup (RR = 0.68; 95% CI, 0.41–1.12) or the ECP subgroup (RR = 0.55; 95% CI, 0.21–1.43) in comparison to the control group. Furthermore, the assessment of heterogeneity indicated no statistical heterogeneity between the SGC and control groups (I2 = 0.00%, H2 = 1.00). Forest plot comparing the recurrence rate of SGC with control. The estimate of recurrence rate included all 11 articles, nine articles for auto-coagulation in situ and two for ECP. Complication rate The overall complication rate was defined as the proportion of eyes that developed graft dehiscence, graft retraction, hemorrhage, granulomas, conjunctival edema, or cyst formation during the follow-up time in each group. Table 2 showed that the overall complication rate ranged from 4% to 48% in the SGC group and from 0% to 27% in the control group. The results shown in Fig. 5 revealed no statistically significant difference in overall complication rate between the SGC and control groups (RR = 1.24; 95% CI, 0.68–2.25). Subgroup analyses showed that neither the auto-coagulation in situ subgroup (RR = 1.48; 95% CI, 0.74–2.96) nor the ECP subgroup (RR = 0.59; 95% CI, 0.28–1.23) differed significantly from the control group. Statistical heterogeneity was observed in the overall analysis (I2 = 63.79%, H2 = 2.76), mainly attributable to the auto-coagulation in situ subgroup (I2 = 65.33%, H2 = 2.88), whereas no heterogeneity was observed in the ECP subgroup (I2 = 0.00%, H2 = 1.00). The meta-regression results presented in Table 3 showed that surgical technique was not a source of heterogeneity (p = 0.311). Forest plot comparing the overall complication rate of SGC with control. The estimate of recurrence rate included all 11 articles, nine articles for auto-coagulation in situ and two for ECP. Table 3Meta-Regression Analysis Results of Surgical Technique.Outcome MeasuresCoefficientStandard ErrortP>|t|95% Confidence IntervalsRecurrence Rate−0.2175770.5551193−0.390.704−1.473344–1.03819Overall Complication Rate−0.81035850.7541113−1.070.311−2.516277–0.8955598Surgical Duration7.1999187.4233250.970.360−9.9183–24.31814 Meta-Regression Analysis Results of Surgical Technique. As shown in Figs. 6, 7 and 8, the SGC group demonstrated a higher incidence of graft dehiscence (RR = 4.73; 95% CI, 1.29–17.28) and graft retraction (RR = 3.09; 95% CI, 1.56–6.15). The incidence of granuloma formation tended to be lower in the SGC group, and the pooled estimate reached borderline statistical significance (RR = 0.48; 95% CI, 0.24–0.99). Forest plot comparing the graft dehiscence rate of SGC with control. Forest plot comparing the graft retraction rate of SGC with control. Forest plot comparing the granuloma formation rate of SGC with control. Surgical duration Table 2 provided the mean (-x) and standard deviation (s) of surgical duration reported in each study. The weighted mean surgical duration was 21.44 min in the SGC group and 30.78 min in the control group. As the study by Tanie Natung (2017)[31 did not report data on surgical duration, it was excluded from this part of the analysis. As demonstrated in Fig. 9, the pooled analysis of surgical duration revealed a statistically significant reduction in the SGC group (MD=−12.79; 95% CI, −18.04–−7.53). Subgroup analyses indicated that both the auto-coagulation in situ subgroup (MD=−14.24; 95% CI, −21.30 to −7.17) and the ECP subgroup (MD=−7.10; 95% CI, −7.74 to −6.45) had significantly shorter surgical duration than the control group. Statistical heterogeneity was observed in the overall analysis (I2 = 99.79%, H2=471.25), mainly driven by the auto-coagulation in situ subgroup (I2 = 99.83%, H2=589.07), whereas the ECP subgroup showed lower heterogeneity (I2 = 36.85%, H2 = 1.58). The results presented in Table 3 indicated that surgical technique was not a significant source of heterogeneity (p = 0.360). Forest plot comparing the surgical duration of SGC with control. The estimate of surgical duration included 10 articles, eight articles for auto-coagulation in situ and two for ECP. “Mean” refers to the average surgical duration, and “SD” refers to the standard deviation, both expressed in minutes. Sensitivity analysis and publication bias Sensitivity analyses in S Table 3 revealed that sequentially excluding individual studies did not significantly alter the pooled estimates of recurrence rate, complication rate, or surgical duration, indicating the robustness of the results. The funnel plots showed a generally symmetrical distribution of studies around the pooled estimates, with most studies lying within the 95% confidence limits (Fig. 10). Although mild asymmetry was observed among several smaller studies, the Harbord test did not detect statistically significant evidence of publication bias for either recurrence rate (p = 0.2477) or overall complication rate (p = 0.3577). As shown in Table 4, after imputing three and two potentially missing studies for recurrence rate and overall complication rate, respectively, the pooled estimates and 95% CIs showed no substantial changes, further supporting the robustness of the results. Funnel plots of included studies assessing the pterygium recurrence rate and complication rate comparing the SGC with control. Table 4Results of the Trim-and-Fill Method.OutcomesPooled Estimate95% Confidence IntervalsRecurrence RateObserved0.6490.415–1.013Observed + Imputed0.7180.468–1.101Overall Complication RateObserved1.2350.679–2.248Observed + Imputed1.0280.555–1.904 Results of the Trim-and-Fill Method. Discussion Pterygium is a challenging condition that can be treated with various surgical procedures, including the bare sclera technique, conjunctival autograft33, and amniotic membrane transplantation34. Additionally, adjuvant surgical treatments involving beta-irradiation35 and mitomycin C36 have been explored due to anti-fibrotic and anti-angiogenic effects37. The high recurrence rate following pterygium surgery remains a pressing concern, and the absence of standardized guidelines for management adds to the complexity of addressing this issue19. It has been observed that approximately 90% of recurrences manifest between the first and third postoperative months38. A minority of recurrences may also occur 6 to 12 months after surgery. The findings of this meta-analysis indicate that SGC may be an effective treatment option for pterygium, with recurrence rates ranging from 0% to 26.7%30,31, which did not significantly differ from those associated with the control group. Although the overall complication rate did not significantly differ between the SGC and control groups, graft dehiscence and graft retraction occurred more frequently in the SGC group, possibly reflecting concerns regarding graft stability. Moreover, the analysis revealed that SGC could effectively reduce surgical duration, which may positively impact patient comfort during the procedure. However, the extremely high heterogeneity observed for surgical duration suggested that the interpretability and clinical applicability of this pooled estimate may be limited. Zein et al.39 conducted a meta-analysis examining conjunctival autograft fixation using autologous blood, fibrin glue, or sutures and highlighted that graft fixation using autologous blood exhibited suboptimal stability but led to improved patient satisfaction and reduced postoperative symptoms. A similar finding was confirmed by Zeng et al.40. Recently, Tsai et al.41 compared fibrin glue with sutures for securing conjunctival autografts in primary pterygium surgery and reported that fibrin glue was associated with reduced recurrence rates and shorter surgical duration. The present meta-analysis also suggests that SGC can shorten surgical duration; however, SGC did not significantly reduce recurrence. In this paper, a novel approach was adopted by introducing the ECP group as a subgroup within the SGC group for meta-analysis. However, since only two studies were included in the ECP subgroup, the results should be considered preliminary. Larger-scale RCTs are warranted to further validate the efficacy and safety of ECP. It is essential to acknowledge certain limitations of this meta-analysis. This meta-analysis was not prospectively registered in PROSPERO or any other publicly accessible registration platform, which may limit methodological transparency and introduce potential selective outcome reporting bias. Databases such as Embase and the Cochrane Library were not searched in the study; therefore, some relevant studies may have been missed. Most of the included studies were conducted in China, India, Egypt, and Nepal, regions in which pterygium may be more frequently encountered due to factors such as ultraviolet light exposure42,43. However, this geographic concentration may limit the external validity and generalizability of the findings to other populations. Three of the included studies had a follow-up time of less than 12 months, which may have contributed to an underestimation of long-term recurrence rates. This variability in follow-up time may have introduced bias and limited the validity of the pooled estimate of the recurrence rate. Another limitation is the lack of a direct comparison with fibrin glue-based conjunctival autograft fixation, which may limit the clinical applicability of the present findings. Finally, statistical measures such as I2 and H2 can only quantify the extent of statistical heterogeneity. Given the differences among the included studies in geographic regions, surgical techniques, and other factors, clinical heterogeneity was expected. Currently, there is no consensus on the optimal surgical method for treating pterygium, highlighting the need for additional clinical studies in this area. This study suggests that SGC may be a viable treatment option for pterygium. Conclusion This meta-analysis of 11 studies revealed that SGC shortened surgical duration without increasing the risk of recurrence compared with the control group in pterygium treatment; however, it was associated with higher rates of graft dehiscence and graft retraction. These findings provide further evidence supporting the use of SGC in the treatment of pterygium. Clinicians should carefully balance the benefits of SGC against the risk of increased complications and determine its suitability based on individual patient characteristics. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Author contributions C.Z.: Conceptualization, Data curation, Formal Analysis, Investigation, Methodology, Software, Visualization, Writing – original draft, Writing – review & editing.Z.C.: Data curation, Investigation, Methodology, Writing – review & editing.J.J.: Project administration, Resources, Writing – review & editing.J.O.: Data curation, Methodology, Writing – review & editing.K.H.: Conceptualization, Funding acquisition, Project administration, Writing – review & editing. Funding This research was funded by National Natural Science Foundation of China (81870695), Natural Science Foundation of Jiangsu Province (BK20241725), Key Program of Nanjing Science and Technology Development Plan (ZKX20022), Nanjing Science and Technology Development Plan (YKK21095), Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University (2022-LCYJ-MS-36) and National Key Research and Development Program of China (2019YFE0111700). Data availability All data generated or analysed during this study are included in this published article (and its Supplementary Information files). Declarations Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Chengxiao Zhang, Zeying Chen and Jiaxuan Jiang. References Associated Data Supplementary Materials Supplementary Material 1 Data Availability Statement All data generated or analysed during this study are included in this published article (and its Supplementary Information files).